fibronectin type III domain containing 5Genealiases: FRCP2 · irisin
Q-omics provides the consensus-scored FNDC5 profile across patient tissues and cancer cell-line models. FNDC5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, FNDC5 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, FNDC5 RNA expression shows 18,066 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where FNDC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNDC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNDC5 survival associations across molecular data types. FNDC5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNDC5 RNA expression–survival associations across cancer types. High FNDC5 expression shows unfavorable associations in COAD and KIRC, but favorable associations in LUAD, KIRP, UCS and PAAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for FNDC5 RNA expression.
This table summarizes FNDC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FNDC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNDC5 shows lower tumor expression in KIRC, KIRP, HNSC, STAD, UCEC and BRCA. The KIRC box plot shows higher FNDC5 RNA expression in normal versus tumor tissue (log2 FC = −1.176, t-test p < 0.001).
This table shows molecular features associated with FNDC5 in patient tissues and cancer cell lines. In patient samples, FNDC5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FNDC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
